KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Operating Leases (2019 - 2025)

Pacific Biosciences Of California (PACB) has 7 years of Operating Leases data on record, last reported at $57.0 million in Q4 2025.

  • For Q4 2025, Operating Leases rose 282.46% year-over-year to $57.0 million; the TTM value through Dec 2025 reached $57.0 million, up 282.46%, while the annual FY2025 figure was $57.0 million, 282.46% up from the prior year.
  • Operating Leases reached $57.0 million in Q4 2025 per PACB's latest filing, up from $54.3 million in the prior quarter.
  • Across five years, Operating Leases topped out at $57.0 million in Q4 2025 and bottomed at $14.9 million in Q4 2024.
  • Average Operating Leases over 5 years is $38.7 million, with a median of $39.0 million recorded in 2023.
  • Peak YoY movement for Operating Leases: tumbled 52.81% in 2024, then skyrocketed 282.46% in 2025.
  • A 5-year view of Operating Leases shows it stood at $50.0 million in 2021, then dropped by 17.81% to $41.1 million in 2022, then decreased by 23.04% to $31.6 million in 2023, then crashed by 52.81% to $14.9 million in 2024, then surged by 282.46% to $57.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $57.0 million in Q4 2025, $54.3 million in Q3 2025, and $52.9 million in Q1 2025.